Navigation Links
Memory Pharmaceuticals Regains Compliance with NASDAQ Market Capitalization Requirement
Date:12/16/2008

MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that the NASDAQ Listing and Hearing Review Council has determined that the Company has demonstrated compliance with The NASDAQ Capital Market requirement for market value of listed securities. As a result, the Company's securities will continue to trade on The NASDAQ Capital Market pending a determination by the NASDAQ Listing Qualifications Panel regarding the Company's compliance with the minimum bid price requirement.

In October 2008, NASDAQ temporarily suspended its minimum bid price requirement due to extraordinary market conditions. As part of this temporary suspension, the Panel granted Memory Pharmaceuticals until February 2, 2009 to regain compliance with the minimum bid price requirement.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materiall
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Study Disputes Ongoing Controversy Over Memory Screenings
2. Unlocking the mysteries of memory
3. Memory Pharmaceuticals Receives NASDAQ Decisions
4. Memory Formation Different in Those With Stress-Related Psychiatric Disorders
5. Stress-related disorders affect brain’s processing of memory
6. Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
7. Super aged brains reveal first secrets of sharp memory in old age
8. Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
9. Memory Pharmaceuticals to Announce Third Quarter 2008 Results on Thursday, November 13, 2008
10. Leading London Neurosurgeon, Sim Farar, Partners with Los Angeles Fitness Guru to Help Baby Boomers Decrease Memory Loss
11. Alzheimers Foundation of America Offers Free Memory Screenings Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 2Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 3Health News:New Jersey Doctors Now Delivering Non-Invasive, Image-Guided Radiosurgery Treatments Using Novalis Tx(TM) Technology 4Health News:Feeding America and Abbott Partner For Hurricane Relief 2Health News:Feeding America and Abbott Partner For Hurricane Relief 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 2Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 4Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 5Health News:Pain Medicine Experts Recommend Monitoring, Education for All Opioid Medicines 2Health News:Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support 2Health News:Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support 3Health News:The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation 2Health News:The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation 3
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 1Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 2Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 3Insect resistance to Bt crops can be predicted monitored and managed 61927 1Insect resistance to Bt crops can be predicted monitored and managed 61927 2Research and legislation should go hand in hand as much as possible 10861 1Research and legislation should go hand in hand as much as possible 10861 2